Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The first data that demonstrates a clear link between the Haptoglobin gene and vascular disease in diabetics has been published. This data supports HaptoGuard's development of its drug, BXT-51072, for this indication.
Subscribe to our email newsletter
The research compared diabetic animal models that were designed to express different variants of Hp. An animal model that expresses the Hp2 variant shows greater vascular damage, than an animal model that expresses the Hp1 variant of the protein.
HaptoGuard intends to examine the efficacy of BXT-51072 applied to the diabetic, Hp2 mouse. Hp2 in the context of diabetes identifies patients at increased risk of death and heart failure following heart attack. Positive efficacy results from such a study would further support the Company’s choice to develop BXT-50172 in cardiovascular disease.